Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the “Notification Letter”)
Polarean Imaging PLC (AIM:POLX) FDA Approves XENOVIEWT (Xe 129 hyperpolarized)
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the evaluation of lung ventilation
Evgen Pharma PLC (AIM:EVG) Study started of new SFX-01 tablet formulation
First healthy volunteers dosed on schedule
Evgen Pharma PLC (AIM:EVG) SFX-01 licensing deal for up to $160.5m
SFX-01 licensing deal for up to $160.5m in milestone payments expands lead asset into neurodevelopmental disorders
MGC Pharmaceuticals (ASX:LON:MXC) Clinical Study results – patients with Long COVID
Clinical Study results on the influence
Midatech Pharma PLC (AIM:MTPH) MTX110 Development for the Treatment of Glioma
Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma
Midatech Pharma PLC (AIM:MTPH) Proposed New Chairman – MTX110 Study to be Presented
Midatech Pharma (MTPH), an R&D biotechnology company, said that Rolf Stahel, Chairman and non-executive director, intends to retire after the company’s AGM on 20 June 2022.
Evgen Pharma PLC (EVG.L) Progress with UK and US regulators for 2022 trials
Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of cancers and inflammation, announces that it has progressed discussions with the
Feedback PLC (FDBK.L) Partnership with Amazon Web Services
Feedback receives funding from Amazon Web Services in support of its cloud-based tuberculosis screening programme for rural communities in India
Women are pushing forward groundbreaking Alzheimer’s treatment ideas that go beyond the headlines
The medical community is now closer than ever to finding treatments for Alzheimer’s disease.
Evgen Pharma PLC (EVG.L) Publication of data in glioblastoma cells
Publication shows effectiveness of SFX-01 in patient derived glioblastoma cells University of Auckland data